EP3166596A1 — Pharmaceutical dosage forms
Assigned to Novartis AG · Expires 2017-05-17 · 9y expired
What this patent protects
The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5 H -pyrrolo[1,2- c ]imidazol-5-yl]-3- fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid p…
USPTO Abstract
The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5 H -pyrrolo[1,2- c ]imidazol-5-yl]-3- fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.